Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 12/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7265955 | 0.88 | CA12 (0.32) | CA12CA1CA14CA2CTSK | |
| SCHEMBL3287414 | 0.86 | CTSK (0.32) | CA12CA1CA14CA2CTSK | |
| SCHEMBL6889561 | 0.85 | CA12 (0.37) | CA12CA1CA14CA2CTSK | |
| SCHEMBL3288389 | 0.85 | TDP1 (0.41) | CA12CA1CA14CA2CTSK | |
| SCHEMBL3290851 | 0.84 | CTSK (0.37) | CA12CA1CA14CA2CTSK | |
| SCHEMBL3290471 | 0.77 | CA12 (0.32) | CA12CA1CA14CA2 | |
| SCHEMBL3293189 | 0.75 | CAPN1 (0.39) | CA12CA1CA14CA2CTSK | |
| SCHEMBL3861382 | 0.73 | CTSK (0.41) | CA12CA1CA14CTSKCTSS | |
| SCHEMBL3861385 | 0.73 | CTSK (0.41) | CA12CA1CA14CTSKCTSS | |
| SCHEMBL7260635 | 0.73 | TDP1 (0.36) | CA12CA1CA14CA2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-6583301-B1 | Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo | CELLTECH R & D LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
| EP-1204428-A2 | TARGETED LIPID PARTICLES | Celltech R&D Limited (GB) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001012154-A2 | TARGETED LIPID PARTICLES | CELLTECH R&D LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| EP-1070047-A2 | LIPIDS | Celltech Chiroscience Limited (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052858-A2 | LIPIDS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | CA12 1777/4885CA1 1771/4885CA14 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.